Related references
Note: Only part of the references are listed.Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN
Eileen Morgan et al.
GUT (2023)
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Mauro Poggio et al.
CELL (2019)
Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance
Zhipeng Su et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer
Laura Mezquita et al.
JAMA ONCOLOGY (2018)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen et al.
NATURE (2018)
A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
Lee S. Rosen et al.
CLINICAL CANCER RESEARCH (2017)
Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells
Katharine D. Grugan et al.
MABS (2017)
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Sydney R. Gordon et al.
NATURE (2017)
A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer
Zu-Jun Sun et al.
ONCOTARGET (2017)
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
M. Ilie et al.
ANNALS OF ONCOLOGY (2016)
PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κB
Lavakumar Karyampudi et al.
CANCER RESEARCH (2016)
Immunotherapy for breast cancer: past, present, and future
Alison Spellman et al.
CANCER AND METASTASIS REVIEWS (2016)
The coming of age of engineered multivalent antibodies
Natalia Nunez-Prado et al.
DRUG DISCOVERY TODAY (2015)
Redirection of CD4+and CD8+T lymphocytes via an anti-CD3 x anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells
Dongmei Fan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future
Gaurav Goel et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion
Hui-Hui Cao et al.
MOLECULAR CANCER (2015)
Alternative molecular formats and therapeutic applications for bispecific antibodies
Christoph Spiess et al.
MOLECULAR IMMUNOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma
Steven N. Steinway et al.
PLOS ONE (2015)
Immune Modulation in Cancer with Antibodies
David B. Page et al.
ANNUAL REVIEW OF MEDICINE, VOL 65 (2014)
Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles
Raimond Heukers et al.
BIOMATERIALS (2014)
Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Developing biomarkers to predict benefit from HGF/MET pathway inhibitors
Hartmut Koeppen et al.
JOURNAL OF PATHOLOGY (2014)
MM-141, an IGF-IR- and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors
Jonathan B. Fitzgerald et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer
Jessica J. Tao et al.
SCIENCE SIGNALING (2014)
A Phase I, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 × CD3 dual-affinity re-targeting (DART®) protein in patients with relapsed/refractory metastatic colorectal carcinoma
Herbert Hurwitz et al.
Journal for ImmunoTherapy of Cancer (2014)
Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results
R. Schoffelen et al.
BRITISH JOURNAL OF CANCER (2013)
Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
Mark Merchant et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody
Shuhui Wang et al.
CANCER LETTERS (2012)
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
Hector Peinado et al.
NATURE MEDICINE (2012)
Targeting MET in cancer: rationale and progress
Ermanno Gherardi et al.
NATURE REVIEWS CANCER (2012)
c-Met Represents a Potential Therapeutic Target for Personalized Treatment in Hepatocellular Carcinoma
Hanning You et al.
HEPATOLOGY (2011)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
Biochemical Characterization of AMG 102: A Neutralizing, Fully Human Monoclonal Antibody to Human and Nonhuman Primate Hepatocyte Growth Factor
Teresa L. Burgess et al.
MOLECULAR CANCER THERAPEUTICS (2010)
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
I Kryczek et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Met, metastasis, motility and more
C Birchmeier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Share Paper
